The immune system is a complex defense network that continuously seeks balance to keep our bodies healthy. An overly active immune response, mainly driven by dysregulated B cells and/or T cells, is thought to cause many #autoimmune diseases. CD19-directed T cell engagers are a promising modality for depleting B cells, with disease-modifying potential for patients with certain autoimmune diseases.    Learn more about our investigation into targeting CD19 with T cell engagers for autoimmune diseases: https://bit.ly/3CclIMY #ACR24

Don’t miss us at #ACR24! Stop by our booth (#2304) to meet our team and learn more about our work in #autoimmune diseases.     Tomorrow, we’ll be presenting preclinical data evaluating CLN-978, our CD19xCD3 bispecific T cell engager, and its potential as a treatment for autoimmune diseases like systemic lupus erythematosus (#SLE).     Get more details on our presentation here: https://bit.ly/3OavTEw

Despite advances in #autoimmune disease research, there remains an unmet need for treatments that provide durable remission for patients. Learn more about our investigation into CD19-directed T cell engagers in an effort to create new standards of care for patients with autoimmune diseases like systemic lupus erythematosus (#SLE).    Visit our booth (#2304) at #ACR24 or view our fact sheet to learn more about our research: https://bit.ly/3NYguHj

Today, we shared preclinical data evaluating CLN-978, our CD19xCD3 bispecific T cell engager. These data will be presented at #ACR24 on Saturday, November 16, between 10:30 a.m. and 12:30 p.m. ET. Learn more: https://bit.ly/4fxb5mL

#Autoimmune disease drug development is seeing renewed innovation and interest, paving the way for more flexible, patient-friendly therapies. Emerging options like T cell engagers show potential as off-the-shelf treatments. In this article with BioPharma Dive, industry experts including our Chief Medical Officer Jeff Jones, MD, MBA, explore how a modality-agnostic approach and innovation-without-borders philosophy better enables the rapid, strategic advancement of potential new standards of care for patients. Read the full article: https://bit.ly/4fGuVvz

We’re pleased to introduce the newest member of our #ScientificAdvisoryBoard, Chaim Putterman, MD, MBA, Professor Emeritus of Medicine, Microbiology and Immunology, Albert Einstein College of Medicine and Montefiore Medical Center.     Dr. Putterman’s extensive expertise and major research interests are in the field of #immunology and #autoimmune diseases, specifically the identification and characterization of novel mechanisms, biomarkers, and treatment approaches to lupus nephritis, neuropsychiatric lupus, and systemic lupus erythematosus (SLE).     We look forward to Dr. Putterman’s expertise and passion for advancing new treatments in autoimmune diseases as we continue our investigation of CLN-978 in SLE.     Meet our full Scientific Advisory Board: https://bit.ly/4amtj6W 

We’re pleased to welcome Professor Ricardo Grieshaber-Bouyer, MD, PhD, MHBA, Head of the Clinical Trial Unit at FAU Erlangen-Nuremberg, to our #ScientificAdvisoryBoard.    Professor Grieshaber-Bouyer cares for patients with rheumatic and immune-mediated diseases, particularly in the context of emerging therapies such as T cell redirecting therapies.    In addition to joining our Scientific Advisory Board, Professor Grieshaber-Bouyer is also a clinical collaborator on our CLN-978 program.   We look forward to strengthening our partnership and leveraging his expertise as we continue our expansion into #autoimmune diseases.   Watch a Q&A with Professor Grieshaber-Bouyer, where he discusses his work in autoimmune diseases with Jeff Jones, MD, MBA, our Chief Medical Officer: https://bit.ly/3Ol9Efr

Despite innovations in biologics and small molecules, current therapies for autoimmune diseases like systemic lupus erythematous (SLE) often only provide short-term symptom control. Patients need treatments that deliver more durable remissions. In this article with Springer Nature, we explore: 🔹The overactive immune response, driven by B cells and/or T cells, and how this may contribute to the pathogenesis of autoimmune diseases. 🔹T cell engagers (TCEs) as a promising modality to deliver deep B cell depletion for autoimmune disease where pathogenic B cells play a key role. 🔹Our investigation of a CD19-targeted TCE which may provide a convenient, off-the-shelf option with the potential to improve upon current standards of care. Read the full article: https://bit.ly/48DPw16

Today at #SITC24, we’re excited to present new biomarker and translational data for CLN-619, our novel investigational anti-MICA/B antibody being evaluated across multiple indications in solid tumors and hematologic malignancies. Learn more here: https://bit.ly/3YX1AYh

Today, we shared Q3 2024 financial results. We are making meaningful progress in executing our strategic plans for CLN-978 in #autoimmune diseases while simultaneously advancing our #oncology pipeline. Learn more: https://bit.ly/4eqazW9